Multiple Myeloma Insights

Real-World Data Reveals Myeloma Treatment Outcomes, Patient Burden, and Preferences

The article discusses real-world data on multiple myeloma treatment, focusing on survivorship, the burden of the disease, and patient preferences. It highlights the importance of understanding patient experiences and preferences to improve treatment outcomes and quality of life for those with multiple myeloma.

High-Fiber Diet Shows Promise in Smoldering Myeloma Patients

Dr. Van den Brink discusses a study exploring the impact of a high-fiber dietary intervention on patients with smoldering multiple myeloma, highlighting potential benefits in delaying disease progression. The research aims to understand how dietary changes can influence the immune system and overall health in these patients.

Access Disparities to CAR-T Cell Therapy in Minority Myeloma Patients

Dr. Ruella discusses the disparities in access to CAR-T cell therapy for minority patients with multiple myeloma, highlighting the need for greater equity in treatment availability. She emphasizes the importance of addressing these disparities to improve outcomes for all patients.

Choosing the Right CAR-T Therapy for Relapsed/Refractory Patients

The article discusses the various CAR-T cell therapies available for relapsed or refractory multiple myeloma patients, highlighting key considerations and criteria for selecting the most appropriate treatment. It emphasizes patient-specific factors, such as disease characteristics and prior treatments, to guide healthcare providers in making informed decisions.

Recent studies have provided new insights into the treatment and prognosis of multiple myeloma. Almaguer (2025) has shown that low-dose teclistamab can be an effective consolidation treatment for patients with newly diagnosed multiple myeloma, suggesting a potential new strategy for early-stage disease management.

Meanwhile, Li et al. (2025) have identified that the presence of 1q21 gain/amplification is associated with a poorer prognosis, and they have developed a risk scoring system that could help stratify patients based on their prognostic outlook.

In advanced cases, Leiser (2025) reports that anitocabtagene autoleucel has shown durable efficacy and a manageable safety profile in high-risk, heavily pretreated patients, offering hope for those with relapsed or refractory disease.